Lichen sclerosus is a chronic inflammatory disorder that most often affects the anogenital skin. In vulvar disease, patients may experience marked hypopigmentation, thinning, textural change, itching, soreness, fissuring, pain with intercourse, and gradual architectural change if the condition is not recognized and managed over time.

The source article emphasizes that this is not a trivial irritation disorder. Untreated disease may lead to adhesions, narrowing, loss of normal vulvar architecture, and an increased risk of differentiated vulvar intraepithelial neoplasia and vulvar squamous cell carcinoma. For that reason, AnnaHealth should treat lichen sclerosus as a major scientific knowledge article inside the Center of Excellence, not just as a brief overview card.

Lichen sclerosus can occur across the lifespan, including childhood, but the source article notes two commonly discussed peaks of presentation: prepubertal girls and postmenopausal women. At the same time, the disease is not limited to those groups, and milder or subtler disease in premenopausal adults may contribute to under-recognition and delayed diagnosis.

True prevalence is hard to measure because patients may present to gynecology, dermatology, pediatrics, or urology, and many cases are never formally reported. That uncertainty is one reason a strong native AnnaHealth article matters: patients often search by symptoms first, not by confirmed diagnosis.

The exact cause remains uncertain. The source article reviews several theories, including immune dysregulation, autoimmune association, genetic predisposition, altered cytokine signaling, oxidative stress, and possible changes in basement membrane biology. It also notes that infectious theories have been proposed but not confirmed.

For AnnaHealth readers, the most important takeaway is that lichen sclerosus appears to be a biologically complex inflammatory disease rather than a hygiene problem or a simple estrogen-deficiency condition. That framing helps reduce stigma and supports the need for longitudinal follow-up when the diagnosis is established.

Itching is one of the hallmark symptoms and may become severe enough to disrupt sleep and daily function. Patients may also experience soreness, burning, dysuria, dyspareunia, pain with defecation, fissuring, or discomfort related to scratching and secondary erosions. Some patients are minimally symptomatic until scarring or narrowing becomes more advanced.

Classic examination patterns include ivory-white papules or plaques, thinning or thickened skin, ecchymoses from scratching, fissures, and a crinkled or sometimes smooth shiny texture. With progression, the labia minora may adhere or become effaced, the clitoris may become buried, and introital narrowing may develop. The vagina itself is typically not involved, though mucocutaneous junctions can narrow.

The source article makes clear that lichen sclerosus is frequently confused with recurrent yeast, nonspecific irritation, or normal anatomic variation. Pigment change, fissuring, and itching may be attributed to other causes, and patients may not realize that gradual architectural change is pathologic.

A strong AnnaHealth-native article should therefore help readers recognize why persistent itching, whitening, fissuring, labial change, painful sex, or clitoral architectural change deserve specialist evaluation instead of repeated self-treatment alone.

One of the most important scientific points in the source material is the association between vulvar lichen sclerosus and vulvar neoplasia. The article reviews literature suggesting a measurable risk of malignant transformation, with differentiated vulvar intraepithelial neoplasia regarded as an important precursor pathway in some patients.

Just as important, the source highlights that long-term surveillance and treatment adherence matter. Some observational work described malignancy occurring predominantly in non-compliant or insufficiently followed patients. The practical AnnaHealth takeaway is that lichen sclerosus is a chronic disease requiring lifelong management and periodic reassessment, not a short one-time treatment episode.

The companion treatment plan emphasizes general vulvar care, avoidance of irritants, topical comfort support, and super-potent topical corticosteroid ointment as the mainstay of treatment, with titration down to maintenance dosing once control is achieved. Mid-potency steroids may be used in more sensitive areas such as peri-anal skin, and flares often require temporary re-escalation.

The source also notes the need to check pH, microscopy, and yeast culture when appropriate, to consider biopsy if diagnosis is uncertain or lesions look atypical, and to look for superimposed infection during flares. Alternative therapies such as calcineurin inhibitors may be considered in selected or recalcitrant cases, but the overall message is that treatment is chronic, structured, and follow-up dependent.

This page is the AnnaHealth-native rendering of the core scientific lichen sclerosus article. It is intentionally written as real repository content rather than a migration placeholder, so the middle CoE reading experience can stand on its own inside AnnaHealth.

The next layer of migration should add a separate native AnnaHealth treatment-plan page for lichen sclerosus, plus native image/figure handling and companion patient-handout content, so users can move from disease article to treatment article to patient education without ever leaving the Center of Excellence.